Novartis (NVS)
(Delayed Data from NYSE)
$104.92 USD
-0.75 (-0.71%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $104.94 +0.02 (0.02%) 4:28 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$104.92 USD
-0.75 (-0.71%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $104.94 +0.02 (0.02%) 4:28 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
Zacks News
Novartis (NVS) Arm's Biosimilars Study Results Encourage
by Zacks Equity Research
Novartis (NVS) generic arm, Sandoz, reported positive data from two phase III studies evaluating biosimilars of Humira and MabThera respectively.
Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised
by Zacks Equity Research
Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.
Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y
by Zacks Equity Research
Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.
Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus
by Zacks Equity Research
Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.
What's in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology that helps it form partnerships with several leading healthcare companies might drive the stock in Q3.
Teva (TEVA) Stock Plunges 20% on Q3 Earnings Miss & View Cut
by Zacks Equity Research
Teva's (TEVA) third-quarter earnings missed estimates while revenues were in line. The company lowered its earnings and revenue guidance for 2017, for the second time this year.
Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss
by Zacks Equity Research
Conatus (CNAT) reports wider-than-expected loss in Q3. However, revenues significantly increased year over year.
Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept's (ICPT) third-quarter results were encouraging as loss was narrower than expected while Ocaliva registered a sequential increase.
5 Biotech and Pharma Stocks with Key FDA Catalysts this November
by Arpita Dutt
Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.
Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal
by Zacks Equity Research
Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.
Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss
by Zacks Equity Research
Aduro BioTech's (ADRO) third-quarter results were unimpressive with the company reporting loss as expected and revenues missing estimates.
Novartis Buys French Radiopharmaceutical Company
by Zacks Equity Research
Novartis (NVS) plans to acquire France-based Advanced Accelerator Applications. The takeover will add RadioLigand Therapy, Lutathera, in its portfolio with potential to drive growth in the near term.
Advanced Accelerator (AAAP) in Focus: Stock Moves 10.4% Higher
by Zacks Equity Research
Advanced Accelerator (AAAP) was a big mover last session, as the company saw its shares more than 10% on the day amid huge volumes.
What's in Store for Juno Therapeutics (JUNO) in Q3 Earnings?
by Zacks Equity Research
Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q3.
Foreign Stock Roundup: Novartis, Bayer, Glaxo, Total Beat on Earnings
by Swarup Gupta
Political developments guided the movement of most non U.S. markets this week.
What's in Store for Conatus (CNAT) This Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q3. However, the company's current portfolio shows no approved product and revenue generation.
The Zacks Analyst Blog Highlights: Visa, Coca-Cola, United Technologies, AT&T and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Coca-Cola, United Technologies, AT&T and Novartis
Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss
by Zacks Equity Research
The Medicines Company (MDCO) incurs loss in the third quarter of 2017. The top line decreases year over year due to low Angiomax sales.
Amgen (AMGN) Q3 Earnings Top, Sales Decline Y/Y, Stock Falls
by Zacks Equity Research
Though Amgen (AMGN) beat estimates on both earnings & sales and raised its earnings outlook, shares declined in after-hours trading due to the year-over-year decline in revenues.
Drug Stock Q3 Earnings Roster for Oct 26: GILD, BMY & More
by Zacks Equity Research
Four major biotech giants are set to report third-quarter results on Oct 26. A sneak preview as to how things are shaping up for these companies.
Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength
by Zacks Equity Research
Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.
Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to Q3 earnings as evident from J&J's encouraging results. Let's see if some of the other leading players - Amgen, Glaxo and Vertex - follow suit.
Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider
by Arpita Dutt
Will the FDA approval of Novartis and Gilead's (GILD) CAR-T cell therapies fuel more partnership deals and acquisitions in this space?
Key Predictions for Q3 Earnings Reports of LLY, BIIB, NVS
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to the Q3 earnings season as evident from J&J's solid results. Let's see if the other leading players -- Lilly, Biogen and Novartis -- follow suit.
Roche (RHHBY) Reports Sales Numbers for First 9 Months
by Zacks Equity Research
Roche Holding AG's (RHHBY) reported sales of CHF39.4 billion in the first nine months of 2017, up 5% from the year-ago period.